Subscribe To
HGEN / Humanigen to Present at BIO CEO & Investor Conference
HGEN News
By Proactive Investors
July 28, 2023
Humanigen stock removed from S&P Total Market Index as firm faces bankruptcy
Humanigen Inc shares have plummeted more than 90% over the past month, and now trades at a little over a penny per share, after the clinical-stage bio more_horizontal
By InvestorPlace
July 25, 2023
Why Is Humanigen (HGEN) Stock Down 72% Today?
Humanigen (NASDAQ: HGEN ) stock is falling hard on Tuesday after the company warned investors it can't keep listing requirements. According to a fili more_horizontal
By Zacks Investment Research
April 17, 2023
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia
Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilu more_horizontal
By InvestorPlace
August 29, 2022
Why Is Humanigen (HGEN) Stock Down 16% Today?
Source: shutterstock.com/PhotobyTawat Humanigen (NASDAQ: HGEN ) stock is heading lower on Monday as investors react to a delisting notice from the Nas more_horizontal
By Zacks Investment Research
July 14, 2022
Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal
The NIAID's ACTIV-5/BET-B study evaluating Humanigen's (HGEN) lenzilumab plus remdesivir in hospitalized COVID-19 patients fails to meet the primary e more_horizontal
By Benzinga
July 13, 2022
HC Wainwright Downgrades Humanigen On Disappointing COVID-19 Study - What's Next
HC Wainwright downgraded Humanigen Inc (NASDAQ: HGEN) to Neutral from Buy and removed the price target based on the removal of COVID-19 from lenzil more_horizontal
By InvestorPlace
July 13, 2022
Why Is Humanigen (HGEN) Stock Plunging 79% Today?
Humanigen (HGEN) stock is falling hard on Wednesday following the release of preliminary results from a Covid-19 clinical trial. The post Why Is Human more_horizontal
By Market Watch
July 13, 2022
Humanigen's stock tumbles 67% after sharing new clinical data for its COVID-19 treatment
Shares of Humanigen Inc. plunged 67.9% in premarket trading on Wednesday, the day after the company said a National Institutes of Health clinical tria more_horizontal